

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled) A method of replacing, in whole or in part, in a non-human eukaryotic cell, an endogenous immunoglobulin variable region gene locus with an homologous or orthologous human gene locus comprising:
 - a) obtaining a large cloned genomic fragment containing, in whole or in part, the homologous or orthologous human gene locus;
 - b) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (a) to create a large targeting vector for use in the eukaryotic cells (LTVEC);
 - c) introducing the LTVEC of (b) into the eukaryotic cells to replace, in whole or in part, the endogenous immunoglobulin variable gene locus; and
 - d) using a quantitative assay to detect modification of allele (MOA) in the eukaryotic cells of (c) to identify those eukaryotic cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human gene locus.
2. (Canceled) The method of claim 1 further comprising:
 - e) obtaining a large cloned genomic fragment containing a part of the homologous or orthologous human gene locus that differs from the fragment of (a);
 - f) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (e) to create a second LTVEC;
 - g) introducing the second LTVEC of (f) into the eukaryotic cells identified in step (d) to replace, in whole or in part, the endogenous immunoglobulin variable gene locus; and
 - h) using a quantitative assay to detect modification of allele (MOA) in the eukaryotic cells of (g) to identify those eukaryotic cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human gene locus.
3. (Canceled) The method of claim 2 wherein steps (e) through (h) are repeated until the endogenous immunoglobulin variable region gene locus is replaced in whole with an homologous or orthologous human gene locus.

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

4. (Canceled) The method of claim 1 wherein the immunoglobulin variable gene locus is a locus selected from the group consisting of :

- a) a variable gene locus of the kappa light chain;
- b) a variable gene locus of the lambda light chain; and
- c) a variable gene locus of the heavy chain.

5. (Canceled) The method of claim 4 wherein the quantitative assay comprises quantitative PCR, FISH, comparative genomic hybridization, isothermic DNA amplification, or quantitative hybridization to an immobilized probe.

6. (Canceled) The method of claim 5 wherein the quantitative PCR comprises TaqMan® technology or quantitative PCR using molecular beacons.

7. (Canceled) A method of replacing, in whole or in part, in a mouse embryonic stem cell, an endogenous immunoglobulin variable region gene locus with its homologous or orthologous human gene locus comprising:

- a) obtaining a large cloned genomic fragment containing, in whole or in part, the homologous or orthologous human gene locus;
- b) using bacterial homologous recombination to genetically modify the large cloned genomic fragment of (a) to create a large targeting vector for use in the embryonic stem cells;
- c) introducing the large targeting vector of (b) into mouse embryonic stem cells to replace, in whole or in part, the endogenous immunoglobulin variable gene locus in the cells; and
- d) using a quantitative PCR assay to detect modification of allele (MOA) in the mouse embryonic stem cells of (c) to identify those mouse embryonic stem cells in which the endogenous variable gene locus has been replaced, in whole or in part, with the homologous or orthologous human gene locus.

8. (Canceled) The method of claim 7 further comprising:

- e) obtaining a large cloned genomic fragment containing a part of the homologous or orthologous human gene locus that differs from the fragment of (a);
- f) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (e) to create a large targeting vector for use in the embryonic stem cells;

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

g) introducing the large targeting vector of (f) into the mouse embryonic stem cells identified in step (d) to replace, in whole or in part, the endogenous immunoglobulin variable gene locus; and

h) using a quantitative assay to detect modification of allele (MOA) in the mouse embryonic stem cells of (g) to identify those mouse embryonic stem cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human gene locus.

9. (Canceled) The method of claim 8 wherein steps (e) through (h) are repeated until the endogenous immunoglobulin variable region gene locus is replaced in whole with an homologous or orthologous human gene locus.

10. (Canceled) The method of claim 7 wherein the immunoglobulin variable gene locus comprises a locus selected from the group consisting of

- a) a variable gene locus of the kappa light chain;
- b) a variable gene locus of the lambda light chain; and
- c) a variable gene locus of the heavy chain.

11. (Canceled) A genetically modified immunoglobulin variable region gene locus produced by the method of claim 1, 4, 7, or 10.

12. (Canceled) A genetically modified eukaryotic cell comprising a genetically modified immunoglobulin variable region gene locus produced by the method of claim 1, 4, 7 or 10.

13. (Canceled) A non-human organism comprising a genetically modified immunoglobulin variable region gene locus produced by the method of claim 1, 4, 7 or 10.

14. (Canceled) A mouse embryonic stem cell containing a genetically modified immunoglobulin variable region gene locus produced by the method of claim 7 or 10.

15. (Canceled) An embryonic stem cell of claim 14 wherein the mouse heavy chain variable region locus is replaced, in whole or in part, with a human heavy chain variable gene locus.

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

16. (Canceled) An embryonic stem cell of claim 14 wherein the mouse kappa light chain variable region locus is replaced, in whole or in part, with a human kappa light chain variable region locus.

17. (Canceled) An embryonic stem cell of claim 14 wherein the mouse lambda light chain variable region locus is replaced, in whole or in part, with a human lambda light chain variable region locus.

18. (Canceled) An embryonic stem cell of claim 14 wherein the heavy and light chain variable region gene loci are replaced, in whole, with their human homologs or orthologs.

19. (Canceled) A mouse produced from the embryonic stem cell of claim 15.

20. (Canceled) A mouse produced from the embryonic stem cell of claim 16.

21. (Canceled) A mouse produced from the embryonic stem cell of claim 17.

22. (Canceled) A mouse produced from the embryonic stem cell of claim 18.

23. (Canceled) An antibody comprising a human variable region encoded by the genetically modified variable gene locus of claim 11.

24. (Canceled) An antibody of claim 23 further comprising a non-human constant region.

25. (Canceled) An antibody of claim 23 further comprising a human constant region.

26. (Canceled) A transgenic mouse having a genome comprising entirely human heavy and light chain variable region loci operably linked to entirely endogenous mouse constant region loci such that the mouse produces a serum containing an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation.

27. (Canceled) A transgenic mouse having a genome comprising human heavy and/or light chain variable region loci operably linked to endogenous mouse constant region loci such that the

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

mouse produces a serum containing an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation.

28. (Canceled) A transgenic mouse containing an endogenous immunoglobulin variable region locus that has been replaced with an homologous or orthologous human variable region locus, such mouse being produced by a method comprising:

- a) obtaining one or more large cloned genomic fragments that, when combined, span the homologous or orthologous human variable region locus;
- b) using bacterial homologous recombination to genetically modify the cloned genomic fragment(s) of (a) to create large targeting vector(s) for use in mouse embryonic stem cells;
- c) introducing the large targeting vector(s) of (b) into mouse embryonic stem cells to replace the endogenous variable region locus in the cells;
- d) using a quantitative PCR assay to detect modification of allele (MOA) in the mouse embryonic stem cells of (c) to identify those mouse embryonic stem cells in which the endogenous variable region locus has been replaced with the homologous or orthologous human variable region locus;
- e) introducing the mouse embryonic stem cell of (d) into a blastocyst; and
- f) introducing the blastocyst of (e) into a surrogate mother for gestation.

29. (Canceled) The transgenic mouse of claim 27 or 28 wherein the immunoglobulin variable region gene locus comprises one or more loci selected from the group consisting of:

- a) a variable gene locus of the kappa light chain;
- b) a variable gene locus of the lambda light chain; and
- c) a variable gene locus of the heavy chain.

30. (Canceled) The method of claim 7, 8, 9, or 10 wherein the mouse embryonic stem cell is derived from a transgenic mouse produced by the method of claim 28.

31. (Canceled) A method of making a human antibody comprising:

- a) exposing the mouse of claim 26 to antigenic stimulation, such that the mouse produces an antibody against the antigen;
- b) isolating the DNA encoding the variable regions of the heavy and light chains of the antibody;

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

- c) operably linking the DNA encoding the variable regions of (b) to DNA encoding the human heavy and light chain constant regions in a cell capable of expressing active antibodies;
- d) growing the cell under such conditions as to express the human antibody; and
- e) recovering the antibody.

32. (Canceled) The method of claim 31 wherein the cell is a CHO cell.

33. (Canceled) The method of claim 31 wherein said DNA of step (b) is isolated from a hybridoma created from the spleen of the mouse exposed to antigenic stimulation in step (a).

34. (Canceled) The method of claim 31 wherein said DNA is isolated by PCR.

35. (New) A non-human organism comprising a genetically modified immunoglobulin variable region gene locus produced by the method of replacing, in whole or in part, in an isolated non-human eukaryotic cell, an endogenous immunoglobulin variable region gene locus with an homologous or orthologous human immunoglobulin variable gene locus comprising:

- a) obtaining a large cloned genomic fragment greater than 20 kb containing, in whole or in part, the homologous or orthologous human immunoglobulin variable gene locus;
- b) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (a) to create a large targeting vector for use in the eukaryotic cells (LTVEC), the LTVEC having homology arms totaling greater than 20 kb;
- c) introducing the LTVEC of (b) into the isolated eukaryotic cells to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable gene locus; and
- d) using a quantitative assay to detect modification of allele (MOA) in the eukaryotic cells of (c) to identify those eukaryotic cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable gene locus.

36. (New) The non-human organism of claim 35, wherein the immunoglobulin variable region gene locus is a locus selected from the group consisting of:

- a) a variable gene locus of the kappa light chain;
- b) a variable gene locus of the lambda light chain; and
- c) a variable gene locus of the heavy chain.

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

37. (New) The non-human organism of claim 36, which is a mouse.
38. (New) The mouse of claim 37, wherein the heavy and light chain variable region gene loci are replaced, in whole, with their human homologs or orthologs.
39. (New) The non-human organism of claim 36, wherein the non-human eukaryotic cell is a mouse embryonic stem cell.
40. (New) A genetically modified immunoglobulin variable region gene locus produced by the method of replacing, in whole or in part, in an isolated non-human eukaryotic cell, an endogenous immunoglobulin variable region gene locus with an homologous or orthologous human immunoglobulin variable region gene locus comprising:
 - a) obtaining a large cloned genomic fragment greater than 20 kb containing, in whole or in part, the homologous or orthologous human immunoglobulin variable region gene locus;
 - b) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (a) to create a large targeting vector for use in the eukaryotic cells (LTVEC), the LTVEC having homology arms totaling greater than 20 kb;
 - c) introducing the LTVEC of (b) into the isolated eukaryotic cells to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable region gene locus; and
 - d) using a quantitative assay to detect modification of allele (MOA) in the eukaryotic cells of (c) to identify those eukaryotic cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable region gene locus.
41. (New) An antibody comprising a human immunoglobulin variable region encoded by the genetically modified immunoglobulin variable region gene locus of claim 40.
42. (New) An antibody of claim 41 further comprising a non-human constant region.
43. (New) An antibody of claim 41 further comprising a human constant region.

>

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

44. (New) A transgenic mouse having a genome comprising entirely human heavy and light chain immunoglobulin variable region gene loci operably linked to entirely endogenous mouse immunoglobulin constant region gene loci such that the mouse produces a serum containing an antibody comprising a human immunoglobulin variable region and a mouse immunoglobulin constant region in response to antigenic stimulation.

45. (New) A transgenic mouse having a genome comprising human heavy and/or light chain immunoglobulin variable region gene loci operably linked to endogenous mouse immunoglobulin constant region gene loci such that the mouse produces a serum containing an antibody comprising a human immunoglobulin variable region and a mouse immunoglobulin constant region in response to antigenic stimulation.

46. (New) A transgenic mouse containing an endogenous immunoglobulin variable region gene locus that has been replaced with an homologous or orthologous human variable region gene locus, such mouse being produced by a method comprising:

- a) obtaining a large cloned genomic fragment greater than 20 kb containing, in whole or in part, the homologous or orthologous human immunoglobulin variable region gene locus;
- b) using bacterial homologous recombination to genetically modify the cloned genomic fragment of (a) to create a large targeting vector for use in the isolated mouse embryonic stem cells, the large targeting vector having homology arms totaling greater than 20 kb;
- c) introducing the large targeting vector of (b) into the isolated mouse embryonic stem cells to replace by homologous recombination, in whole or in part, the endogenous immunoglobulin variable region gene locus; and
- d) using a quantitative assay to detect modification of allele (MOA) in the mouse embryonic stem cells of (c) to identify those mouse embryonic stem cells in which the endogenous immunoglobulin variable region gene locus has been replaced, in whole or in part, with the homologous or orthologous human immunoglobulin variable region gene locus;
- e) introducing the mouse embryonic stem cells of (d) into a blastocyst; and
- f) introducing the blastocyst of (e) into a surrogate mother for gestation.

47. (New) The transgenic mouse of claim 45 or 46 wherein the immunoglobulin variable region gene locus comprises one or more loci selected from the group consisting of:

- a) a variable gene locus of the kappa light chain;
- b) a variable gene locus of the lambda light chain; and

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

c) a variable gene locus of the heavy chain.

48. (New) A method of making a human antibody comprising:

- a) exposing the mouse of claim 44 to antigenic stimulation, such that the mouse produces an antibody against the antigen;
- b) isolating the DNA encoding the immunoglobulin variable regions of the heavy and light chains of the antibody;
- c) operably linking the DNA encoding the immunoglobulin variable regions of (b) to DNA encoding the human heavy and light chain immunoglobulin constant regions in a cell capable of expressing active antibodies;
- d) growing the cell under such conditions as to express the human antibody; and
- e) recovering the antibody.

49. (New) The method of claim 48 wherein the cell is a CHO cell.

50. (New) The method of claim 48 wherein the DNA of step (b) is isolated from a hybridoma created from the spleen of the mouse exposed to antigenic stimulation in step (a).

51. (New) The method of claim 48 wherein said DNA is isolated by PCR.


52. (New) The mouse embryonic stem cell of claim 39 which is derived from a transgenic mouse of claim 46.

Att. Docket No. REG 780BZ
U.S. File No. Not Yet Known
Filed Herewith
Preliminary Amendment
Murphy, et al.

Fees

No fee is deemed necessary in connection with filing this Preliminary Amendment. However, if any fee is necessary, authorization is hereby given to charge the amount of any such additional fee to Deposit Account No. 18-0650.

Respectfully submitted,



Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

i >